Primary Hyperoxaluria

In recent years, Novo Nordisk has been actively addressing the challenges arising from the launch of its highly popular obesity therapy, Wegovy. However, the pharmaceutical company is now venturing into a less common medical territory with its latest FDA approval. Novo has received FDA approval for Rivfloza, a trea...

AbbVie Presents Results from Phase III CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma AbbVie has released findings from its Phase III CANOVA trial, which assessed the safety and effectiveness of venetoclax (marketed as VENCLEXTA®/VENCLYXTO®) in combination with dexamethasone ...

Primary hyperoxaluria (PH) is a rare autosomal genetic form of Hyperoxaluria, a condition that leads to the excessive urinary excretion of oxalate. Till now, three distinct hereditary enzymatic deficiencies have been identified as a cause of PH, namely, PH type 1 (PH1), type 2 (PH2), and type 3 (PH3), with PH1 as t...